Trial Profile
Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab; Cobimetinib; Paclitaxel; Vemurafenib
- Indications Carcinoma; Liver metastases; Thyroid cancer
- Focus Therapeutic Use
- 20 Jun 2023 Planned End Date changed from 27 Jul 2023 to 31 Jul 2025.
- 20 Jun 2023 Planned primary completion date changed from 27 Jul 2023 to 31 Jul 2025.
- 01 Mar 2023 Status changed from recruiting to active, no longer recruiting.